Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Prostate Cancer

  Free Subscription


Articles published in AJR Am J Roentgenol

Retrieve available abstracts of 129 articles:
HTML format



Single Articles


    May 2021
  1. WEI CG, Zhang YY, Pan P, Chen T, et al
    Diagnostic Accuracy and Interobserver Agreement of PI-RADS Version 2 and Version 2.1 for the Detection of Transition Zone Prostate Cancers.
    AJR Am J Roentgenol. 2021;216:1247-1256.
    PubMed     Abstract available


    April 2021
  2. DENIFFEL D, Haider MA
    Beyond the AJR: "Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography: The IP1-PROSTAGRAM Study".
    AJR Am J Roentgenol. 2021 Apr 28. doi: 10.2214/AJR.21.26048.
    PubMed    


  3. SCIALPI M, Scialpi P, Blasi AD
    Prostate Biparametric MRI: PI-RADS Committee Position and Perspectives.
    AJR Am J Roentgenol. 2021 Apr 21:W1. doi: 10.2214/AJR.21.25443.
    PubMed    


  4. TURKBEY B
    Beyond the AJR: "Comparison of Multiparametric Magnetic Resonance Imaging-Targeted Biopsy with Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer A Phase 3 Randomized Clinical Trial".
    AJR Am J Roentgenol. 2021 Apr 7. doi: 10.2214/AJR.21.25954.
    PubMed    


    March 2021
  5. PARK SY, Shin N
    Reply to "Tumor Topography for Diagnosis of Prostate Cancer".
    AJR Am J Roentgenol. 2021 Mar 31:W1. doi: 10.2214/AJR.21.25476.
    PubMed    


  6. SATISH P, Emberton M, Norris JM
    Tumor Topography for Diagnosis of Prostate Cancer.
    AJR Am J Roentgenol. 2021 Mar 24:W1. doi: 10.2214/AJR.20.25410.
    PubMed    


  7. SIEGEL BA, Schuster DM, Savir-Baruch B
    Using (18)F-Fluciclovine PET/CT to Detect Prostate Cancer Recurrence in Patients With Very Low PSA Levels.
    AJR Am J Roentgenol. 2021;216:W10.
    PubMed    


  8. WANG Y, Scott JA, Palmer EL
    Reply to "Using (18)F-Fluciclovine PET/CT to Detect Prostate Cancer Recurrence in Patients With Very Low PSA Levels".
    AJR Am J Roentgenol. 2021;216:W11.
    PubMed    


    February 2021
  9. CHANG SD, Margolis DJA, Turkbey B, Arnold AA, et al
    Practice Patterns and Challenges of Performing and Interpreting Prostate MRI: A Survey by the Society of Abdominal Radiology Prostate Disease-Focused Panel.
    AJR Am J Roentgenol. 2021 Feb 10:1-8. doi: 10.2214/AJR.20.23256.
    PubMed     Abstract available


    January 2021
  10. CUOCOLO R, Verde F, Ponsiglione A, Romeo V, et al
    Clinically Significant Prostate Cancer Detection With Biparametric MRI: A Systematic Review and Meta-Analysis.
    AJR Am J Roentgenol. 2021 Jan 27:1-14. doi: 10.2214/AJR.20.23219.
    PubMed     Abstract available


  11. CHANG SD
    Editorial Comment: A Close Look at PI-RADS Version 2.1 and Where We Should Go From Here.
    AJR Am J Roentgenol. 2021;216:32.
    PubMed    


  12. PURYSKO AS, Baroni RH, Giganti F, Costa D, et al
    PI-RADS Version 2.1: A Critical Review, From the AJR Special Series on Radiology Reporting and Data Systems.
    AJR Am J Roentgenol. 2021;216:20-32.
    PubMed     Abstract available


  13. USHINSKY A, Bardis M, Glavis-Bloom J, Uchio E, et al
    A 3D-2D Hybrid U-Net Convolutional Neural Network Approach to Prostate Organ Segmentation of Multiparametric MRI.
    AJR Am J Roentgenol. 2021;216:111-116.
    PubMed     Abstract available


    December 2020
  14. SANFORD TH, Zhang L, Harmon SA, Sackett J, et al
    Data Augmentation and Transfer Learning to Improve Generalizability of an Automated Prostate Segmentation Model.
    AJR Am J Roentgenol. 2020;215:1403-1410.
    PubMed     Abstract available


    November 2020
  15. SAVIR-BARUCH B, Choyke PL, Rowe SP, Schuster DM, et al
    Role of (18)F-Fluciclovine and Prostate-Specific Membrane Antigen PET/CT in Guiding Oligometastatic Prostate Cancer Management: AJR Expert Panel Narrative Review.
    AJR Am J Roentgenol. 2020 Nov 18. doi: 10.2214/AJR.20.24711.
    PubMed     Abstract available


    October 2020
  16. GALGANO SJ, McDonald AM, Rais-Bahrami S, Porter KK, et al
    Utility of (18)F-Fluciclovine PET/MRI for Staging Newly Diagnosed High-Risk Prostate Cancer and Evaluating Response to Initial Androgen Deprivation Therapy: A Prospective Single-Arm Pilot Study.
    AJR Am J Roentgenol. 2020 Oct 14. doi: 10.2214/AJR.20.24509.
    PubMed     Abstract available


  17. SHIN N, Park SY
    Postoperative Biochemical Failure in Patients With PI-RADS Category 4 or 5 Prostate Cancers: Risk Stratification According to Zonal Location of an Index Lesion.
    AJR Am J Roentgenol. 2020;215:913-919.
    PubMed     Abstract available


    September 2020
  18. SPILSETH BD
    Editorial Comment on "Prospectively-Reported PI-RADS Version 2.1 Atypical Benign Prostatic Hyperplasia Nodules with Marked Restricted Diffusion ('2+1' Transition Zone Lesions): Clinically Significant Prostate Cancer Detection Rates on Multiparametric
    AJR Am J Roentgenol. 2020 Sep 23. doi: 10.2214/AJR.20.24736.
    PubMed    


  19. UYSAL A, Karaosmanoglu AD, Karcaaltincaba M, Akata D, et al
    Prostatitis, the Great Mimicker of Prostate Cancer: Can We Differentiate Them Quantitatively With Multiparametric MRI?
    AJR Am J Roentgenol. 2020 Sep 9:1-9. doi: 10.2214/AJR.20.22843.
    PubMed     Abstract available


  20. WALKER SM, Mehralivand S, Harmon SA, Sanford T, et al
    Prospective Evaluation of PI-RADS Version 2.1 for Prostate Cancer Detection.
    AJR Am J Roentgenol. 2020 Sep 2:1-6. doi: 10.2214/AJR.19.22679.
    PubMed     Abstract available


  21. GUPTA RT
    Editorial Comment on "Prevalence of prostate cancer in PI-RADS version 2.1 transition zone 'atypical nodules' upgraded by abnormal diffusion weighted imaging: correlation with MRI-directed TRUS-guided targeted biopsy".
    AJR Am J Roentgenol. 2020 Sep 2. doi: 10.2214/AJR.20.24501.
    PubMed    


  22. COSTA DN, Jia L, Subramanian N, Xi Y, et al
    Prospectively-Reported PI-RADS Version 2.1 Atypical Benign Prostatic Hyperplasia Nodules with Marked Restricted Diffusion ('2+1' Transition Zone Lesions): Clinically Significant Prostate Cancer Detection Rates on Multiparametric MRI.
    AJR Am J Roentgenol. 2020 Sep 2. doi: 10.2214/AJR.20.24370.
    PubMed     Abstract available


    August 2020
  23. SCHOOTS IG, Barentsz JO, Bittencourt LK, Haider MA, et al
    PI-RADS Committee Position on MRI Without Contrast Medium in Biopsy Naive Men with Suspected Prostate Cancer: A Narrative Review.
    AJR Am J Roentgenol. 2020 Aug 19. doi: 10.2214/AJR.20.24268.
    PubMed     Abstract available


  24. SURASI DSS
    Editorial Comment on "Diagnostic accuracy of 68Ga-PSMA PET/CT for initial detection in patients with suspected prostate cancer: A systematic review and meta-analysis".
    AJR Am J Roentgenol. 2020 Aug 19. doi: 10.2214/AJR.20.24405.
    PubMed    


  25. MEHRALIVAND S, Harmon SA, Shih JH, Smith CP, et al
    Multicenter Multireader Evaluation of an Artificial Intelligence-Based Attention Mapping System for the Detection of Prostate Cancer With Multiparametric MRI.
    AJR Am J Roentgenol. 2020 Aug 5:1-10. doi: 10.2214/AJR.19.22573.
    PubMed     Abstract available


    July 2020
  26. GEORGE AK, Margolis DJ
    Commentary on "MRI-Targeted, Systematic, and combined Biopsy for Prostate Cancer Diagnosis".
    AJR Am J Roentgenol. 2020 Jul 29. doi: 10.2214/AJR.20.24319.
    PubMed    


  27. LIM CS, Abreu-Gomez J, Carrion I, Schieda N, et al
    Prevalence of prostate cancer in PI-RADS version 2.1 transition zone 'atypical nodules' upgraded by abnormal diffusion weighted imaging: correlation with MRI-directed TRUS-guided targeted biopsy.
    AJR Am J Roentgenol. 2020 Jul 29. doi: 10.2214/AJR.20.23932.
    PubMed     Abstract available


  28. WOO S, Vargas HA
    Commentary on "Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multi-centre study".
    AJR Am J Roentgenol. 2020 Jul 29. doi: 10.2214/AJR.20.23666.
    PubMed    


  29. GIGANTI F, Kirkham A, Allen C, Punwani S, et al
    Update on multiparametric prostate MRI during active surveillance: current and future trends and role of the PRECISE recommendations.
    AJR Am J Roentgenol. 2020 Jul 29. doi: 10.2214/AJR.20.23985.
    PubMed     Abstract available


  30. SATAPATHY S, Singh H, Kumar R, Mittal BR, et al
    Diagnostic accuracy of (68)Ga-PSMA PET/CT for initial detection in patients with suspected prostate cancer: A systematic review and meta-analysis.
    AJR Am J Roentgenol. 2020 Jul 22. doi: 10.2214/AJR.20.23912.
    PubMed     Abstract available


  31. GAUR S, Mena E, Harmon SA, Lindenberg ML, et al
    Prospective Evaluation of (18)F-DCFPyL PET/CT in Detection of High-Risk Localized Prostate Cancer: Comparison With mpMRI.
    AJR Am J Roentgenol. 2020 Jul 8:1-8. doi: 10.2214/AJR.19.22042.
    PubMed     Abstract available


  32. HOSSEINY M, Shakeri S, Felker ER, Lu D, et al
    3-T Multiparametric MRI Followed by In-Bore MR-Guided Biopsy for Detecting Clinically Significant Prostate Cancer After Prior Negative Transrectal Ultrasound-Guided Biopsy.
    AJR Am J Roentgenol. 2020 Jul 8:1-7. doi: 10.2214/AJR.19.22455.
    PubMed     Abstract available


  33. BALLAL S, Yadav MP, Bal C
    Reply to "Fact-Checking on (177)Lu-PSMA Nephrotoxicity".
    AJR Am J Roentgenol. 2020;215:W3-W4.
    PubMed    


  34. ASKARI E, Moghadam SZ, Aryana K
    Fact Checking on (177)Lu Prostate-Specific Membrane Antigen Nephrotoxicity.
    AJR Am J Roentgenol. 2020;215:W2.
    PubMed    


  35. MA HY, Ahmed FS, Luk L, Martina LAP, et al
    The Negative Predictive Value of a PI-RADS Version 2 Score of 1 on Prostate MRI and the Factors Associated With a False-Negative MRI Study.
    AJR Am J Roentgenol. 2020 Jul 1:1-6. doi: 10.2214/AJR.20.22784.
    PubMed     Abstract available


    June 2020
  36. WANG Y, Chow DZ, Ebert E, Tajmir S, et al
    Utility of (18)F-Fluciclovine PET/CT for Detecting Prostate Cancer Recurrence in Patients With Low (< 1 ng/mL) or Very Low (< 0.3 ng/mL) Prostate-Specific Antigen Levels.
    AJR Am J Roentgenol. 2020 Jun 22:1-5. doi: 10.2214/AJR.19.22180.
    PubMed     Abstract available


  37. MARCUS C, Butler P, Bagrodia A, Cole S, et al
    Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management.
    AJR Am J Roentgenol. 2020 Jun 17:1-10. doi: 10.2214/AJR.19.22404.
    PubMed     Abstract available


  38. ABREU-GOMEZ J, Wu M, McInnes MDF, Thornhill RE, et al
    Shape Analysis of Peripheral Zone Observations on Prostate DWI: Correlation to Histopathology Outcomes After Radical Prostatectomy.
    AJR Am J Roentgenol. 2020;214:1239-1247.
    PubMed     Abstract available


    May 2020
  39. GOTHI R
    Unenhanced CT Can Be Enough to Detect Peripheral Zone Prostate Cancer.
    AJR Am J Roentgenol. 2020;214:W84.
    PubMed    


    April 2020
  40. WALKER SM, Choyke PL, Turkbey B
    What You Need to Know Before Reading Multiparametric MRI for Prostate Cancer.
    AJR Am J Roentgenol. 2020 Apr 7:1-9. doi: 10.2214/AJR.19.22751.
    PubMed     Abstract available


    March 2020
  41. LEE DK, Sung DJ, Kim CS, Heo Y, et al
    Three-Dimensional Convolutional Neural Network for Prostate MRI Segmentation and Comparison of Prostate Volume Measurements by Use of Artificial Neural Network and Ellipsoid Formula.
    AJR Am J Roentgenol. 2020 Mar 24:1-10. doi: 10.2214/AJR.19.22254.
    PubMed     Abstract available


  42. DHATT R, Choy S, Co SJ, Ischia J, et al
    MRI of the Prostate With and Without Endorectal Coil at 3 T: Correlation With Whole-Mount Histopathologic Gleason Score.
    AJR Am J Roentgenol. 2020 Mar 11:1-9. doi: 10.2214/AJR.19.22094.
    PubMed     Abstract available


  43. WIBULPOLPRASERT P, Raman SS, Hsu W, Margolis DJA, et al
    Influence of the Location and Zone of Tumor in Prostate Cancer Detection and Localization on 3-T Multiparametric MRI Based on PI-RADS Version 2.
    AJR Am J Roentgenol. 2020 Mar 4:1-11. doi: 10.2214/AJR.19.21608.
    PubMed     Abstract available


  44. BHARGAVA P, Ravizzini G, Chapin BF, Kundra V, et al
    Imaging Biochemical Recurrence After Prostatectomy: Where Are We Headed?
    AJR Am J Roentgenol. 2020 Mar 4:1-11. doi: 10.2214/AJR.19.21905.
    PubMed     Abstract available


    February 2020
  45. PARK SY, Park BK, Kwon GY
    Diagnostic Performance of Mass Enhancement on Dynamic Contrast-Enhanced MRI for Predicting Clinically Significant Peripheral Zone Prostate Cancer.
    AJR Am J Roentgenol. 2020 Feb 18:1-8. doi: 10.2214/AJR.19.22072.
    PubMed     Abstract available


    January 2020
  46. ROBERTSON MS, Sakellis CG, Hyun H, Jacene HA, et al
    Extraprostatic Uptake of (18)F-Fluciclovine: Differentiation of Nonprostatic Neoplasms From Metastatic Prostate Cancer.
    AJR Am J Roentgenol. 2020 Jan 15:1-8. doi: 10.2214/AJR.19.21894.
    PubMed     Abstract available


  47. KIM SH
    Development and External Validation of Multiparametric MRI-Derived Nomogram to Predict Risk of Pathologic Upgrade in Patients on Active Surveillance for Prostate Cancer.
    AJR Am J Roentgenol. 2020 Jan 8:1-10. doi: 10.2214/AJR.19.22196.
    PubMed     Abstract available


  48. WASHINGTON SL 3RD, Baskin AS, Ameli N, Nguyen HG, et al
    MRI-Based Prostate-Specific Antigen Density Predicts Gleason Score Upgrade in an Active Surveillance Cohort.
    AJR Am J Roentgenol. 2020 Jan 8:1-5. doi: 10.2214/AJR.19.21559.
    PubMed     Abstract available


  49. YOSHIDA K, Takahashi N, Karnes RJ, Froemming AT, et al
    Prostatic Remnant After Prostatectomy: MR Findings and Prevalence in Clinical Practice.
    AJR Am J Roentgenol. 2020;214:W37-W43.
    PubMed     Abstract available


  50. TURKBEY B, Czarniecki M, Shih JH, Harmon SA, et al
    Ferumoxytol-Enhanced MR Lymphography for Detection of Metastatic Lymph Nodes in Genitourinary Malignancies: A Prospective Study.
    AJR Am J Roentgenol. 2020;214:105-113.
    PubMed     Abstract available


    December 2019
  51. WOO S, Han S, Kim TH, Suh CH, et al
    Prognostic Value of Pretreatment MRI in Patients With Prostate Cancer Treated With Radiation Therapy: A Systematic Review and Meta-Analysis.
    AJR Am J Roentgenol. 2019 Dec 4:1-8. doi: 10.2214/AJR.19.21836.
    PubMed     Abstract available


  52. CHATTERJEE A, Sun C, Oto A
    Reply to "Prostate Cancer Index Lesion Detection and Volume Estimation: Is Dynamic Contrast-Enhanced MRI Really Reliable?"
    AJR Am J Roentgenol. 2019;213:W290.
    PubMed    


  53. VLACHOU PA
    Reply to "Diagnostic Value of CT in Detecting Peripheral Zone Prostate Cancer: Methodologic Issues to Avoid Misinterpretation".
    AJR Am J Roentgenol. 2019;213:W298.
    PubMed    


  54. SCIALPI M, Scialpi P, Martorana E
    Prostate Cancer Index Lesion Detection and Volume Estimation: Is Dynamic Contrast-Enhanced MRI Really Reliable?
    AJR Am J Roentgenol. 2019;213:W289.
    PubMed    


  55. SABOUR S
    Diagnostic Value of CT in Detecting Peripheral Zone Prostate Cancer: Methodologic Issues to Avoid Misinterpretation.
    AJR Am J Roentgenol. 2019;213:W297.
    PubMed    


    October 2019
  56. BAKIR B, Onay A, Vural M, Armutlu A, et al
    Can Extraprostatic Extension Be Predicted by Tumor-Capsule Contact Length in Prostate Cancer? Relationship With International Society of Urological Pathology Grade Groups.
    AJR Am J Roentgenol. 2019 Oct 31:1-9. doi: 10.2214/AJR.19.21828.
    PubMed     Abstract available


    August 2019
  57. SUBRAMANIAM RM
    Section Editor's Notebook: Prostate Cancer Theranosis in Clinical Practice and in Clinical Trials-(68)Ga-Prostate-Specific Member Antigen (PSMA)-11 PET/CT and (177)Lu-PSMA-617 Therapy.
    AJR Am J Roentgenol. 2019;213:241-242.
    PubMed    


    July 2019
  58. FELKER ER, Raman SS, Lu DSK, Tuttle M, et al
    Utility of Multiparametric MRI for Predicting Residual Clinically Significant Prostate Cancer After Focal Laser Ablation.
    AJR Am J Roentgenol. 2019 Jul 30:1-6. doi: 10.2214/AJR.19.21637.
    PubMed     Abstract available


  59. BARRAL M, Lefevre A, Camparo P, Hoogenboom M, et al
    In-Bore Transrectal MRI-Guided Biopsy With Robotic Assistance in the Diagnosis of Prostate Cancer: An Analysis of 57 Patients.
    AJR Am J Roentgenol. 2019 Jul 3:1-9. doi: 10.2214/AJR.19.21145.
    PubMed     Abstract available


    June 2019
  60. BAJGIRAN AM, Mirak SA, Sung K, Sisk AE, et al
    Apparent Diffusion Coefficient (ADC) Ratio Versus Conventional ADC for Detecting Clinically Significant Prostate Cancer With 3-T MRI.
    AJR Am J Roentgenol. 2019 Jun 19:1-9. doi: 10.2214/AJR.19.21365.
    PubMed     Abstract available


  61. SAVIR-BARUCH B, Lovrec P, Solanki AA, Adams WH, et al
    Fluorine-18-Labeled Fluciclovine PET/CT in Clinical Practice: Factors Affecting the Rate of Detection of Recurrent Prostate Cancer.
    AJR Am J Roentgenol. 2019 Jun 19:1-8. doi: 10.2214/AJR.19.21153.
    PubMed     Abstract available


  62. HUANG G, Lebovic G, Vlachou PA
    Diagnostic Value of CT in Detecting Peripheral Zone Prostate Cancer.
    AJR Am J Roentgenol. 2019 Jun 19:1-5. doi: 10.2214/AJR.18.21013.
    PubMed     Abstract available


  63. ABREU-GOMEZ J, Shabana W, McInnes MDF, O'Sullivan JP, et al
    Regional Standardization of Prostate Multiparametric MRI Performance and Reporting: Is There a Role for a Director of Prostate Imaging?
    AJR Am J Roentgenol. 2019 Jun 10:1-7. doi: 10.2214/AJR.19.21111.
    PubMed     Abstract available


  64. OSMANY S, Zaheer S, Bartel TB, Johnston M, et al
    Gallium-68-Labeled Prostate-Specific Membrane Antigen-11 PET/CT of Prostate and Nonprostate Cancers.
    AJR Am J Roentgenol. 2019 Jun 5:1-14. doi: 10.2214/AJR.19.21084.
    PubMed     Abstract available


    May 2019
  65. ABREU-GOMEZ J, Krishna S, Narayanasamy S, Flood TA, et al
    Dynamic Contrast-Enhanced MRI-Upgraded Prostate ImagingReporting and Data System Version 2 Category 3 Peripheral Zone Observations Stratified by a Size Threshold of 15 mm.
    AJR Am J Roentgenol. 2019 May 23:1-8. doi: 10.2214/AJR.18.21005.
    PubMed     Abstract available


    April 2019
  66. LAWHN-HEATH C, Flavell RR, Behr SC, Yohannan T, et al
    Single-Center Prospective Evaluation of (68)Ga-PSMA-11 PET in Biochemical Recurrence of Prostate Cancer.
    AJR Am J Roentgenol. 2019 Apr 30:1-8. doi: 10.2214/AJR.18.20699.
    PubMed     Abstract available


  67. CHATTERJEE A, He D, Fan X, Antic T, et al
    Diagnosis of Prostate Cancer by Use of MRI-Derived Quantitative Risk Maps: A Feasibility Study.
    AJR Am J Roentgenol. 2019 Apr 30:1-10. doi: 10.2214/AJR.18.20702.
    PubMed     Abstract available


  68. FELKER ER, Raman SS, Shakeri S, Mirak SA, et al
    Utility of Restriction Spectrum Imaging Among Men Undergoing First-Time Biopsy for Suspected Prostate Cancer.
    AJR Am J Roentgenol. 2019 Apr 30:1-6. doi: 10.2214/AJR.18.20836.
    PubMed     Abstract available


  69. GIGANTI F, Rosenkrantz AB, Villeirs G, Panebianco V, et al
    The Evolution of MRI of the Prostate: The Past, the Present, and the Future.
    AJR Am J Roentgenol. 2019 Apr 30:1-13. doi: 10.2214/AJR.18.20796.
    PubMed     Abstract available


  70. WIBULPOLPRASERT P, Raman SS, Hsu W, Margolis DJA, et al
    Detection and Localization of Prostate Cancer at 3-T Multiparametric MRI Using PI-RADS Segmentation.
    AJR Am J Roentgenol. 2019 Apr 17:W1-W10. doi: 10.2214/AJR.18.20113.
    PubMed     Abstract available


  71. YADAV MP, Ballal S, Sahoo RK, Dwivedi SN, et al
    Radioligand Therapy With (177)Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.
    AJR Am J Roentgenol. 2019 Apr 17:1-11. doi: 10.2214/AJR.18.20845.
    PubMed     Abstract available


  72. MEERMEIER NP, Foster BR, Liu JJ, Amling CL, et al
    Impact of Direct MRI-Guided Biopsy of the Prostate on Clinical Management.
    AJR Am J Roentgenol. 2019 Apr 1:1-6. doi: 10.2214/AJR.18.21009.
    PubMed     Abstract available


    March 2019
  73. GREER MD, Shih JH, Lay N, Barrett T, et al
    Interreader Variability of Prostate Imaging Reporting and Data System Version 2 in Detecting and Assessing Prostate Cancer Lesions at Prostate MRI.
    AJR Am J Roentgenol. 2019 Mar 27:1-8. doi: 10.2214/AJR.18.20536.
    PubMed     Abstract available


  74. SWITLYK MD, Salberg UB, Geier OM, Vlatkovic L, et al
    PTEN Expression in Prostate Cancer: Relationship With Clinicopathologic Features and Multiparametric MRI Findings.
    AJR Am J Roentgenol. 2019 Mar 19:1-9. doi: 10.2214/AJR.18.20743.
    PubMed     Abstract available


  75. SACKETT J, Choyke PL, Turkbey B
    Prostate Imaging Reporting and Data System Version 2 for MRI of Prostate Cancer: Can We Do Better?
    AJR Am J Roentgenol. 2019 Mar 19:1-9. doi: 10.2214/AJR.19.21178.
    PubMed     Abstract available


    February 2019
  76. BARKOVICH EJ, Shankar PR, Westphalen AC
    A Systematic Review of the Existing Prostate Imaging Reporting and Data System Version 2 (PI-RADSv2) Literature and Subset Meta-Analysis of PI-RADSv2 Categories Stratified by Gleason Scores.
    AJR Am J Roentgenol. 2019 Feb 26:1-8. doi: 10.2214/AJR.18.20571.
    PubMed     Abstract available


  77. CHOI MH, Kim CK, Lee YJ, Jung SE, et al
    Prebiopsy Biparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2: A Multicenter Study.
    AJR Am J Roentgenol. 2019 Feb 19:1-8. doi: 10.2214/AJR.18.20498.
    PubMed     Abstract available


  78. HOTKER AM, Dappa E, Mazaheri Y, Ehdaie B, et al
    The Influence of Background Signal Intensity Changes on Cancer Detection in Prostate MRI.
    AJR Am J Roentgenol. 2019 Feb 4:1-7. doi: 10.2214/AJR.18.20295.
    PubMed     Abstract available


    January 2019
  79. TANAKA T, Froemming AT, Panda A, Edmonson HA, et al
    Safety and Image Quality of 1.5-T Endorectal Coil Multiparametric MRI of the Prostate or Prostatectomy Fossa for Patients With Pacemaker or Implantable Cardioverter-Defibrillator.
    AJR Am J Roentgenol. 2019 Jan 30:1-8. doi: 10.2214/AJR.18.20266.
    PubMed     Abstract available


    December 2018
  80. FREIFELD Y, Diaz de Leon A, Xi Y, Pedrosa I, et al
    Diagnostic Performance of Prospectively Assigned Likert Scale Scores to Determine Extraprostatic Extension and Seminal Vesicle Invasion With Multiparametric MRI of the Prostate.
    AJR Am J Roentgenol. 2018 Dec 27:1-6. doi: 10.2214/AJR.18.20320.
    PubMed     Abstract available


  81. SUN C, Chatterjee A, Yousuf A, Antic T, et al
    Comparison of T2-Weighted Imaging, DWI, and Dynamic Contrast-Enhanced MRI for Calculation of Prostate Cancer Index Lesion Volume: Correlation With Whole-Mount Pathology.
    AJR Am J Roentgenol. 2018 Dec 12:1-6. doi: 10.2214/AJR.18.20147.
    PubMed     Abstract available


  82. KANG Z, Min X, Weinreb J, Li Q, et al
    Abbreviated Biparametric Versus Standard Multiparametric MRI for Diagnosis of Prostate Cancer: A Systematic Review and Meta-Analysis.
    AJR Am J Roentgenol. 2018 Dec 4:W1-W9. doi: 10.2214/AJR.18.20103.
    PubMed     Abstract available


    November 2018
  83. CHATTERJEE A, Tokdemir S, Gallan AJ, Yousuf A, et al
    Multiparametric MRI Features and Pathologic Outcome of Wedge-Shaped Lesions in the Peripheral Zone on T2-Weighted Images of the Prostate.
    AJR Am J Roentgenol. 2018 Nov 7:1-6. doi: 10.2214/AJR.18.19742.
    PubMed     Abstract available


  84. TURCO S, Lavini C, Heijmink S, Barentsz J, et al
    Evaluation of Dispersion MRI for Improved Prostate Cancer Diagnosis in a Multicenter Study.
    AJR Am J Roentgenol. 2018;211:W242-W251.
    PubMed     Abstract available


  85. COSTA DN, Xi Y, Aziz M, Passoni N, et al
    Prospective Inclusion of Apparent Diffusion Coefficients in Multiparametric Prostate MRI Structured Reports: Discrimination of Clinically Insignificant and Significant Cancers.
    AJR Am J Roentgenol. 2018 Nov 1:1-8. doi: 10.2214/AJR.18.19937.
    PubMed     Abstract available


    October 2018
  86. METSER U, Chan R, Veit-Haibach P, Ghai S, et al
    Comparison of MRI Sequences in Whole-Body PET/MRI for Staging of Patients With High-Risk Prostate Cancer.
    AJR Am J Roentgenol. 2018 Oct 17:W1-W5. doi: 10.2214/AJR.18.20495.
    PubMed     Abstract available


  87. JENA A, Taneja R, Taneja S, Singh A, et al
    Improving Diagnosis of Primary Prostate Cancer With Combined (68)Ga-Prostate-Specific Membrane Antigen-HBED-CC Simultaneous PET and Multiparametric MRI and Clinical Parameters.
    AJR Am J Roentgenol. 2018 Oct 9:1-8. doi: 10.2214/AJR.18.19585.
    PubMed     Abstract available


    September 2018
  88. WOO S, Suh CH, Kim SY, Cho JY, et al
    Head-to-Head Comparison Between Biparametric and Multiparametric MRI for the Diagnosis of Prostate Cancer: A Systematic Review and Meta-Analysis.
    AJR Am J Roentgenol. 2018 Sep 21:W1-W15. doi: 10.2214/AJR.18.19880.
    PubMed     Abstract available


    August 2018
  89. DIAZ DE LEON A, Leyendecker JR, Otero-Muinelo S, Grewal H, et al
    Reproducibility of Index Lesion Size and Mean Apparent Diffusion Coefficient Values Measured by Prostate Multiparametric MRI: Correlation With Whole-Mount Sectioning of Specimens.
    AJR Am J Roentgenol. 2018 Aug 30:1-6. doi: 10.2214/AJR.17.19172.
    PubMed     Abstract available


  90. WANG X, Tu N, Qin T, Xing F, et al
    Diffusion Kurtosis Imaging Combined With DWI at 3-T MRI for Detection and Assessment of Aggressiveness of Prostate Cancer.
    AJR Am J Roentgenol. 2018 Aug 7:W1-W8. doi: 10.2214/AJR.17.19249.
    PubMed     Abstract available


    July 2018
  91. LEE SJ, Oh YT, Jung DC, Cho NH, et al
    Combined Analysis of Biparametric MRI and Prostate-Specific Antigen Density: Role in the Prebiopsy Diagnosis of Gleason Score 7 or Greater Prostate Cancer.
    AJR Am J Roentgenol. 2018 Jul 17:W1-W7. doi: 10.2214/AJR.17.19253.
    PubMed     Abstract available


  92. WESTIN C, Chatterjee A, Ku E, Yousuf A, et al
    MRI Findings After MRI-Guided Focal Laser Ablation of Prostate Cancer.
    AJR Am J Roentgenol. 2018 Jul 11:1-10. doi: 10.2214/AJR.17.19201.
    PubMed     Abstract available


  93. QI L, Wu CJ, Zhang J, Bao ML, et al
    Construction of a Preoperative Radiologic-Risk Signature for Predicting the Pathologic Status of Prostate Cancer at Radical Prostatectomy.
    AJR Am J Roentgenol. 2018 Jul 11:1-7. doi: 10.2214/AJR.17.19360.
    PubMed     Abstract available


  94. SADOUGHI N, Krishna S, McInnes MDF, Flood TA, et al
    ADC Metrics From Multiparametric MRI: Histologic Downgrading of Gleason Score 9 or 10 Prostate Cancers Diagnosed at Nontargeted Transrectal Ultrasound-Guided Biopsy.
    AJR Am J Roentgenol. 2018 Jul 11:W1-W8. doi: 10.2214/AJR.17.18958.
    PubMed     Abstract available


    June 2018
  95. HOPE TA, Afshar-Oromieh A, Eiber M, Emmett L, et al
    Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications.
    AJR Am J Roentgenol. 2018 Jun 27:1-9. doi: 10.2214/AJR.18.19957.
    PubMed     Abstract available


  96. NIU XK, Chen XH, Chen ZF, Chen L, et al
    Diagnostic Performance of Biparametric MRI for Detection of Prostate Cancer: A Systematic Review and Meta-Analysis.
    AJR Am J Roentgenol. 2018 Jun 12:1-10. doi: 10.2214/AJR.17.18946.
    PubMed     Abstract available


  97. SCIALPI M, Aisa MC, D'Andrea A, Martorana E, et al
    Simplified Prostate Imaging Reporting and Data System for Biparametric Prostate MRI: A Proposal.
    AJR Am J Roentgenol. 2018 Jun 12:1-4. doi: 10.2214/AJR.17.19014.
    PubMed     Abstract available


  98. MCEVOY SH, Raeside MC, Chaim J, Ehdaie B, et al
    Preoperative Prostate MRI: A Road Map for Surgery.
    AJR Am J Roentgenol. 2018 Jun 12:W1-W9. doi: 10.2214/AJR.17.18757.
    PubMed     Abstract available


  99. ORTMAN M, Kasson M, Sidana A
    Prostate Cancer and Prostate Imaging Reporting and Data System Category 3 Lesions Identified at Multiparametric Prostate MRI.
    AJR Am J Roentgenol. 2018;210:W268.
    PubMed    


  100. SHERIDAN AD, Weinreb JC, Spektor M
    Reply to "Prostate Cancer and Prostate Imaging Reporting and Data System Category 3 Lesions Identified at Multiparametric Prostate MRI".
    AJR Am J Roentgenol. 2018;210:W269.
    PubMed    


    May 2018
  101. SI Y, Liu RB
    Diagnostic Performance of Monoexponential DWI Versus Diffusion Kurtosis Imaging in Prostate Cancer: A Systematic Review and Meta-Analysis.
    AJR Am J Roentgenol. 2018 May 29:1-11. doi: 10.2214/AJR.17.18934.
    PubMed     Abstract available


    April 2018
  102. KIM JG, Kim CK, Kim JH
    Prebiopsy Multiparametric MRI With Cancer-Negative Findings in Men With Suspected Prostate Cancer: Evaluation Using Prostate Imaging Reporting and Data System Version 2.
    AJR Am J Roentgenol. 2018 Apr 30:1-6. doi: 10.2214/AJR.17.18926.
    PubMed     Abstract available


  103. LEE MS, Moon MH, Kim YA, Sung CK, et al
    Is Prostate Imaging Reporting and Data System Version 2 Sufficiently Discovering Clinically Significant Prostate Cancer? Per-Lesion Radiology-Pathology Correlation Study.
    AJR Am J Roentgenol. 2018 Apr 27:1-7. doi: 10.2214/AJR.17.18684.
    PubMed     Abstract available


    March 2018
  104. TANEJA S, Jena A, Taneja R, Singh A, et al
    Effect of Combined (68)Ga-PSMAHBED-CC Uptake Pattern and Multiparametric MRI Derived With Simultaneous PET/MRI in the Diagnosis of Primary Prostate Cancer: Initial Experience.
    AJR Am J Roentgenol. 2018 Mar 12:1-8. doi: 10.2214/AJR.17.18881.
    PubMed     Abstract available


    February 2018
  105. COSTA DN, Passoni NM, Leyendecker JR, de Leon AD, et al
    Diagnostic Utility of a Likert Scale Versus Qualitative Descriptors and Length of Capsular Contact for Determining Extraprostatic Tumor Extension at Multiparametric Prostate MRI.
    AJR Am J Roentgenol. 2018 Feb 28:1-7. doi: 10.2214/AJR.17.18849.
    PubMed     Abstract available


  106. SHERIDAN AD, Nath SK, Aneja S, Syed JS, et al
    MRI-Ultrasound Fusion Targeted Biopsy of Prostate Imaging Reporting and Data System Version 2 Category 5 Lesions Found False-Positive at Multiparametric Prostate MRI.
    AJR Am J Roentgenol. 2018 Feb 28:W1-W8. doi: 10.2214/AJR.17.18680.
    PubMed     Abstract available


    January 2018
  107. WOO S, Suh CH, Kim SY, Cho JY, et al
    The Diagnostic Performance of MRI for Detection of Lymph Node Metastasis in Bladder and Prostate Cancer: An Updated Systematic Review and Diagnostic Meta-Analysis.
    AJR Am J Roentgenol. 2018 Jan 30:W1-W15. doi: 10.2214/AJR.17.18481.
    PubMed     Abstract available


  108. METSER U, Berlin A, Halankar J, Murphy G, et al
    (18)F-Fluorocholine PET Whole-Body MRI in the Staging of High-Risk Prostate Cancer.
    AJR Am J Roentgenol. 2018 Jan 11:1-6. doi: 10.2214/AJR.17.18567.
    PubMed     Abstract available


    December 2017
  109. NIU XK, Chen ZF, Chen L, Li J, et al
    Clinical Application of Biparametric MRI Texture Analysis for Detection and Evaluation of High-Grade Prostate Cancer in Zone-Specific Regions.
    AJR Am J Roentgenol. 2017 Dec 8:W1-W8. doi: 10.2214/AJR.17.18494.
    PubMed     Abstract available


    November 2017
  110. PARVINIAN A, Martin-Macintosh EL, Goenka AH, Durski JM, et al
    11C-Choline PET/CT for Detection and Localization of Parathyroid Adenomas.
    AJR Am J Roentgenol. 2017 Nov 15:1-5. doi: 10.2214/AJR.17.18312.
    PubMed     Abstract available


  111. SHERIDAN AD, Nath SK, Syed JS, Aneja S, et al
    Risk of Clinically Significant Prostate Cancer Associated With Prostate Imaging Reporting and Data System Category 3 (Equivocal) Lesions Identified on Multiparametric Prostate MRI.
    AJR Am J Roentgenol. 2017 Nov 7:1-11. doi: 10.2214/AJR.17.18516.
    PubMed     Abstract available


    October 2017
  112. TAMADA T, Huang C, Ream JM, Taffel M, et al
    Apparent Diffusion Coefficient Values of Prostate Cancer: Comparison of 2D and 3D ROIs.
    AJR Am J Roentgenol. 2017 Oct 18:1-5. doi: 10.2214/AJR.17.18495.
    PubMed     Abstract available


  113. KRISHNA S, McInnes M, Lim C, Lim R, et al
    Comparison of Prostate Imaging Reporting and Data System Versions 1 and 2 for the Detection of Peripheral Zone Gleason Score 3 + 4 = 7 Cancers.
    AJR Am J Roentgenol. 2017 Oct 5:W1-W9. doi: 10.2214/AJR.17.17964.
    PubMed     Abstract available


    September 2017
  114. WOO S, Suh CH, Kim SY, Cho JY, et al
    Head-To-Head Comparison Between High- and Standard-b-Value DWI for Detecting Prostate Cancer: A Systematic Review and Meta-Analysis.
    AJR Am J Roentgenol. 2017 Sep 27:1-10. doi: 10.2214/AJR.17.18480.
    PubMed     Abstract available


    August 2017
  115. FELKER ER, Raman SS, Margolis DJ, Lu DSK, et al
    Risk Stratification Among Men With Prostate Imaging Reporting and Data System Version 2 Category 3 Transition Zone Lesions: Is Biopsy Always Necessary?
    AJR Am J Roentgenol. 2017 Aug 31:1-6. doi: 10.2214/AJR.17.18008.
    PubMed     Abstract available


  116. WU CJ, Zhang YD, Bao ML, Li H, et al
    Diffusion Kurtosis Imaging Helps to Predict Upgrading in Biopsy-Proven Prostate Cancer With a Gleason Score of 6.
    AJR Am J Roentgenol. 2017 Aug 23:1-7. doi: 10.2214/AJR.16.17781.
    PubMed     Abstract available


  117. WOO S, Suh CH, Kim SY, Cho JY, et al
    Shear-Wave Elastography for Detection of Prostate Cancer: A Systematic Review and Diagnostic Meta-Analysis.
    AJR Am J Roentgenol. 2017 Aug 10:1-9. doi: 10.2214/AJR.17.18056.
    PubMed     Abstract available


  118. JADVAR H
    Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment.
    AJR Am J Roentgenol. 2017;209:277-288.
    PubMed     Abstract available


    July 2017
  119. SHERIDAN AD, Nath SK, Huber S, Rosasco S, et al
    Role of MRI in the Use of an Absorbable Hydrogel Spacer in Men Undergoing Radiation Therapy for Prostate Cancer: What the Radiologist Needs to Know.
    AJR Am J Roentgenol. 2017 Jul 25:1-3. doi: 10.2214/AJR.17.18026.
    PubMed     Abstract available


  120. KIM SH, Choi MS, Kim MJ, Kim YH, et al
    Validation of Prostate Imaging Reporting and Data System Version 2 Using an MRI-Ultrasound Fusion Biopsy in Prostate Cancer Diagnosis.
    AJR Am J Roentgenol. 2017 Jul 13:1-6. doi: 10.2214/AJR.16.17629.
    PubMed     Abstract available


    June 2017
  121. GLAZER DI, Mayo-Smith WW, Sainani NI, Sadow CA, et al
    Interreader Agreement of Prostate Imaging Reporting and Data System Version 2 Using an In-Bore MRI-Guided Prostate Biopsy Cohort: A Single Institution's Initial Experience.
    AJR Am J Roentgenol. 2017 Jun 28:W1-W7. doi: 10.2214/AJR.16.17551.
    PubMed     Abstract available


  122. MORGAN VA, Parker C, MacDonald A, Thomas K, et al
    Monitoring Tumor Volume in Patients With Prostate Cancer Undergoing Active Surveillance: Is MRI Apparent Diffusion Coefficient Indicative of Tumor Growth?
    AJR Am J Roentgenol. 2017 Jun 13:1-9. doi: 10.2214/AJR.17.17790.
    PubMed     Abstract available


  123. GANESHAN D, Aparicio AM, Morani A, Kundra V, et al
    Pattern and Distribution of Distant Metastases in Anaplastic Prostate Carcinoma: A Single-Institute Experience With 101 Patients.
    AJR Am J Roentgenol. 2017 Jun 7:1-6. doi: 10.2214/AJR.16.17214.
    PubMed     Abstract available


  124. MATSUOKA Y, Ishioka J, Tanaka H, Kimura T, et al
    Impact of the Prostate Imaging Reporting and Data System, Version 2, on MRI Diagnosis for Extracapsular Extension of Prostate Cancer.
    AJR Am J Roentgenol. 2017 Jun 1:W1-W9. doi: 10.2214/AJR.16.17163.
    PubMed     Abstract available


  125. PURYSKO AS, Bittencourt LK, Bullen JA, Mostardeiro TR, et al
    Accuracy and Interobserver Agreement for Prostate Imaging Reporting and Data System, Version 2, for the Characterization of Lesions Identified on Multiparametric MRI of the Prostate.
    AJR Am J Roentgenol. 2017 Jun 1:1-7. doi: 10.2214/AJR.16.17289.
    PubMed     Abstract available


    April 2017
  126. SEO JW, Shin SJ, Taik Oh Y, Jung DC, et al
    PI-RADS Version 2: Detection of Clinically Significant Cancer in Patients With Biopsy Gleason Score 6 Prostate Cancer.
    AJR Am J Roentgenol. 2017 Apr 18:W1-W9. doi: 10.2214/AJR.16.16981.
    PubMed     Abstract available


    February 2017
  127. VENDERINK W, Govers TM, de Rooij M, Futterer JJ, et al
    Cost-Effectiveness Comparison of Imaging-Guided Prostate Biopsy Techniques: Systematic Transrectal Ultrasound, Direct In-Bore MRI, and Image Fusion.
    AJR Am J Roentgenol. 2017 Feb 22:1-6. doi: 10.2214/AJR.16.17322.
    PubMed     Abstract available


    December 2016
  128. ROSENKRANTZ AB, Ayoola A, Hoffman D, Khasgiwala A, et al
    The Learning Curve in Prostate MRI Interpretation: Self-Directed Learning Versus Continual Reader Feedback.
    AJR Am J Roentgenol. 2016 Dec 27:W1-W9. doi: 10.2214/AJR.16.16876.
    PubMed     Abstract available


    August 2016
  129. KIRSCH AJ, Coakley FV, Foster BR
    A Modified Approach for Transgluteal Prostate Biopsy in Patients Without Rectal Access.
    AJR Am J Roentgenol. 2016;207:W20.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: